8,518 Shares in Natera, Inc. $NTRA Bought by Private Advisory Group LLC

Private Advisory Group LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 8,518 shares of the medical research company’s stock, valued at approximately $3,521,000.

Several other large investors have also made changes to their positions in NTRA. BlackRock Inc. bought a new stake in shares of Natera during the 2nd quarter valued at approximately $2,962,770,000. Arrowstreet Capital Limited Partnership raised its position in Natera by 1.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after purchasing an additional 11,793 shares during the last quarter. Maverick Capital Ltd. boosted its stake in shares of Natera by 24.1% during the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after purchasing an additional 227,605 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Natera by 10.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after purchasing an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Natera during the second quarter worth about $199,960,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NTRA shares. Rothschild & Co Redburn assumed coverage on shares of Natera in a report on Tuesday, September 8th. They issued a “buy” rating and a $385.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Barclays lifted their price target on shares of Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, BTIG Research boosted their price objective on shares of Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research note on Tuesday, October 27th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $394.31.

Natera Stock Up 1.0%

NTRA opened at $322.94 on Friday. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The company has a fifty day moving average of $379.87 and a 200-day moving average of $271.22. The stock has a market cap of $46.83 billion, a PE ratio of -283.28 and a beta of 1.55.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The firm had revenue of $793.98 million for the quarter, compared to the consensus estimate of $707.54 million. Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. Natera’s quarterly revenue was up 34.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.64) EPS. Sell-side analysts anticipate that Natera, Inc. will post -1.25 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, CFO Michael Brophy sold 470 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $391.49, for a total value of $184,000.30. Following the transaction, the chief financial officer owned 45,779 shares of the company’s stock, valued at approximately $17,922,020.71. This trade represents a 1.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,419 shares of Natera stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $409.77, for a total value of $1,401,003.63. Following the transaction, the insider directly owned 101,323 shares in the company, valued at approximately $41,519,125.71. The trade was a 3.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 47,056 shares of company stock worth $17,760,989. 5.05% of the stock is currently owned by insiders.

Natera Profile

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.